Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 11/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 11/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 8/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957694 | 0.85 | MCL1 (0.58) | PKMCACNA1GCACNA1HCACNA1IMCL1 | |
| SCHEMBL24018796 | 0.81 | ALDH1A1 (0.54) | MEN1KMT2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL13875905 | 0.81 | HTT (0.51) | HTTPKMMEN1KMT2ASLC6A2 | |
| SCHEMBL24018825 | 0.81 | CACNA1G (0.43) | PKMCACNA1GCACNA1HCACNA1IMCL1 | |
| SCHEMBL10245660 | 0.81 | HTT (0.57) | HTTPKMMEN1KMT2AALOX15 | |
| SCHEMBL22957693 | 0.81 | ATM (0.46) | CACNA1GCACNA1HCACNA1ISLC6A2SLC6A4 | |
| SCHEMBL22389474 | 0.79 | RIPK1 (0.57) | HTTMEN1KMT2ACACNA1GCACNA1H | |
| SCHEMBL5413155 | 0.79 | L3MBTL1 (0.55) | MEN1KMT2ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL12201562 | 0.79 | ALDH1A1 (0.59) | HTTALDH1A1 | |
| SCHEMBL22957643 | 0.78 | HTT (0.48) | HTTPKMMEN1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | HTT 4152/4885PKM 561/4885MEN1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.